A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab (FCFD4514S) in Patients With Geographic Atrophy Who Have Completed Genentech-Sponsored Lampalizumab Studies
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Lampalizumab (Primary)
- Indications Dry age-related macular degeneration
- Focus Adverse reactions
- Sponsors Genentech
- 14 Aug 2018 The trial status changed to discontinue.
- 15 Jan 2018 Planned primary completion date changed from 29 Jun 2019 to 24 Jan 2018.
- 12 Dec 2017 This trial has been Discontinued in Germany , according to European Clinical Trials Database